Web Stats Provided By Google Analytics

Sunday, March 31, 2013

Repros Moves Up On Phase III Data, Both Co-Endpoints Met

Thursday, we saw shares of the developmental biopharmaceutical company Repros Therapeutics close over 76% higher by the closing bell, reacting to a press release issued by the company after Wednesday's trading.

http://seekingalpha.com/article/1310281-repros-moves-up-on-phase-iii-data-both-co-endpoints-met?source=feed

No comments:

Post a Comment

Popular Healthcare Law Roundup Posts